Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity [Seeking Alpha]
Sagimet Biosciences Inc. (SGMT)
Company Research
Source: Seeking Alpha
Revenue generated so far comes from licensing agreements, and no product sales are anticipated in the near future. SGMT's leading drug candidate, denifanstat, is progressing to phase 3 with successful trial results, targeting MASH, a leading cause of liver transplants. SGMT's balance sheet shows a cash runway of about 3.3 years, sufficient for Phase 3 trials. Still, I'm somewhat concerned due to a high rate of TEAEs related to denifanstat. Despite risks associated with clinical trials and adverse events, SGMT is a strong buy with significant upside potential in MASH. Sagimet Biosciences Inc. ( NASDAQ: SGMT ) is a clinical-stage biopharmaceutical company researching a cure for metabolic dysfunction-related diseases by inhibiting fatty acid synthase [FASN]. This approach targets the overproduction of fatty acids, contributing to conditions like acne, metabolic dysfunction-associated steatohepatitis [MASH], and certain cancers. Denifanstat is progressing to phase 3 with successf
Show less
Read more
Impact Snapshot
Event Time:
SGMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMT alerts
High impacting Sagimet Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SGMT
News
- Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024GlobeNewswire
- Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial OfficerGlobeNewswire
- Sagimet Biosciences Inc. (NASDAQ: SGMT) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $32.00 price target on the stock.MarketBeat
- Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 [Yahoo! Finance]Yahoo! Finance
SGMT
Sec Filings
- 5/8/24 - Form 4
- 5/8/24 - Form 3
- 5/6/24 - Form 8-K
- SGMT's page on the SEC website